Chronic myeloid leukemia stem cells and developing therapies

References

• Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808–4817.
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–172.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie ‘addiction’ to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006;10:425–435.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009:461–476.
   PubMedGoogle Scholar
• Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16:122–131.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834–848.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Papayannidis C, Soverini S. New targets for Ph+ leukaemia therapy. Best Pract Res Clin Haematol 2009;22:445–454.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program 2009;477–487.
   PubMedGoogle Scholar
• Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009;453–460.
   PubMedGoogle Scholar
• Radich JP. Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting. Clin Lymphoma Myeloma 2009;9(Suppl. 4):S391–S394.
   PubMedGoogle Scholar
• Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 2010 Oct 19. [Epub ahead of print].
   Google Scholar
• Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008;8:341–350.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319–325.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010;24:1545–1554.
   Google Scholar
• Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol 2010;47:362–370.
   PubMed Web of Science ®Google Scholar
• Copland M. Chronic myelogenous leukemia stem cells: what's new? Curr Hematol Malig Rep 2009;4:66–73.
   PubMedGoogle Scholar
• Helgason GV, Young GA, Holyoake TL. Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep 2010;5:81–87.
   PubMedGoogle Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–111.
   PubMed Web of Science ®Google Scholar
• Eaves CJ. Cancer stem cells: here, there, everywhere? Nature 2008;456:581–582.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645–648.
   PubMed Web of Science ®Google Scholar
• Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998;91:2406–2414.
   PubMed Web of Science ®Google Scholar
• Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005;19:435–441.
   PubMed Web of Science ®Google Scholar
• Cross NCP, Daley GQ, Green AR, et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 2008;22:1975–1989.
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005;105:324–334.
   PubMed Web of Science ®Google Scholar
• Perez-Caro M, Cobaleda C, Gonzalez-Herrero I, et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 2009;28:8–20.
   PubMedGoogle Scholar
• Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039–1050.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110–114.
   PubMed Web of Science ®Google Scholar
• Gunsilius E, Duba H-C, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000;355:1688–1691.
   PubMed Web of Science ®Google Scholar
• Fang B, Zheng C, Liao L, et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 2005;105:2733–2740.
   PubMed Web of Science ®Google Scholar
• Wu J, Huang L, Huang M, et al. Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia. Exp Hematol 2009;37:87–91.
   Google Scholar
• Otten J, Schultze A, Schafhausen P, et al. Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. Br J Haematol 2008;142:115–118.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Lubbert M, Guo Y. CD34(+) or CD34(−): which is the more primitive? Leukemia 2002;16:1603–1608.
   PubMed Web of Science ®Google Scholar
• Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 2009;114:5191–5200.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719–1724.
   PubMed Web of Science ®Google Scholar
• Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007;18:459–471.
   PubMed Web of Science ®Google Scholar
• Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992;79:1920–1923.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 1995;91:126–131.
   PubMed Web of Science ®Google Scholar
• Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? Leukemia 2010 Sep16. [Epub ahead of print].
   Web of Science ®Google Scholar
• Schemionek M, Elling C, Steidl U, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010;115:3185–3195.
   PubMed Web of Science ®Google Scholar
• Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009;114:1150–1157.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009;12:103–113.
   PubMed Web of Science ®Google Scholar
• Wang P-Y, Young F, Chen C-Y, et al. The biological properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood 2008;112:4184–4192.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 2009;113:1250–1256.
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010;463:676–680.
   PubMed Web of Science ®Google Scholar
• Mulloy JC, Cancelas JA, Filippi M-D, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010;115:936–947.
   PubMed Web of Science ®Google Scholar
• Sahay S, Pannucci NL, Mahon GM, et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008;27:2064–2071.
   PubMed Web of Science ®Google Scholar
• Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007;12:467–478.
   PubMed Web of Science ®Google Scholar
• Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 2010;116:81–84.
   PubMed Web of Science ®Google Scholar
• Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528–541.
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen Y, Douglas L, Li S. Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009;23:109–116.
   PubMed Web of Science ®Google Scholar
• Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238–249.
   PubMed Web of Science ®Google Scholar
• Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776–779.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Yamasaki N, Miyazaki K, et al. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice. Oncogene 2008;27:3465–3474.
   PubMed Web of Science ®Google Scholar
• Nakahara F, Sakata-Yanagimoto M, Komeno Y, et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 2010;115:2872–2881.
   PubMed Web of Science ®Google Scholar
• Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood 2008;111:492–503.
   PubMed Web of Science ®Google Scholar
• ter Huurne M, Figdor CG, Torensma R. Hematopoietic stem cells are coordinated by the molecular cues of the endosteal niche. Stem Cells Dev 2010;19:1131–1141.
   PubMed Web of Science ®Google Scholar
• Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010;7:150–161.
   PubMed Web of Science ®Google Scholar
• Eliasson P, Jönsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010;222:17–22.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kimura S, Kuroda J, et al. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ 2010;17:1211–1220.
   Google Scholar
• Klawitter J, Kominsky DJ, Brown JL, et al. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 2009;158:588–600.
   PubMed Web of Science ®Google Scholar
• Zhao F, Mancuso A, Bui TV, et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010;29:2962–2972.
   PubMed Web of Science ®Google Scholar
• Wittig R, Coy JF. The role of glucose metabolism and glucose-associated signalling in cancer. Perspect Medicin Chem 2008;1:64–82.
   PubMedGoogle Scholar
• Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010;7:380–390.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009;29:625–634.
   PubMed Web of Science ®Google Scholar
• Takubo K, Goda N, Yamada W, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010;7:391–402.
   PubMed Web of Science ®Google Scholar
• Parmar K, Mauch P, Vergilio J-A, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007;104:5431–5436.
   PubMed Web of Science ®Google Scholar
• Winkler IG, Barbier V, Wadley R, Zannettino ACW, Williams S, Levesque J-P. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010;116:375–385.
   PubMed Web of Science ®Google Scholar
• Kaufman DS. HIF hits Wnt in the stem cell niche. Nat Cell Biol 2010;12:926–927.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472–482.
   PubMed Web of Science ®Google Scholar
• Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009;69:2163–2166.
   PubMed Web of Science ®Google Scholar
• Kim Y-W, Koo B-K, Jeong H-W, et al. Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood 2008;112:4628–4638.
   PubMed Web of Science ®Google Scholar
• Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007;129:1097–1110.
   PubMed Web of Science ®Google Scholar
• Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475–482.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MHGP, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010;464:852–857.
   PubMed Web of Science ®Google Scholar
• Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126–139.
   PubMed Web of Science ®Google Scholar
• Mani R-S, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
   PubMed Web of Science ®Google Scholar
• Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069–1083.
   PubMed Web of Science ®Google Scholar
• Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010;7:174–185.
   PubMed Web of Science ®Google Scholar
• Milyavsky M, Gan OI, Trottier M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 2010;7:186–197.
   PubMed Web of Science ®Google Scholar
• Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008;13:483–495.
   PubMed Web of Science ®Google Scholar
• Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766–774.
   PubMed Web of Science ®Google Scholar
• O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679–1689.
   PubMed Web of Science ®Google Scholar
• Fitter S, Dewar A, Kostakis P. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538–2547.
   PubMed Web of Science ®Google Scholar
• Tibullo D, Giallongo C, La Cava P. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009;37:461–468.
   Google Scholar
• Vandyke K, Dewar A, Farrugia A. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994–997.
   PubMed Web of Science ®Google Scholar
• Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008;7:48–58.
   PubMed Web of Science ®Google Scholar
• Chute JP. Stem cell homing. Curr Opin Hematol 2006;13:399–406.
   PubMed Web of Science ®Google Scholar
• Ptasznik A, Urbanowska E, Chinta S, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 2002;196:667–678.
   PubMed Web of Science ®Google Scholar
• Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol 2008;26:2911–2915.
   Google Scholar
• Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593–598.
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701–4707.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58–60.
   PubMed Web of Science ®Google Scholar
• Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006;103:16870–16875.
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532–4539.
   PubMed Web of Science ®Google Scholar
• Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007;109:4016–4019.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008;100:926–939.
   PubMed Web of Science ®Google Scholar
• Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306–314.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227–34239.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690–698.
   PubMed Web of Science ®Google Scholar
• Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009;28:1669–1681.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008;111:3821–3829.
   PubMed Web of Science ®Google Scholar
• Zimmerman EI, Dollins CM, Crawford M, et al. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol 2010;78:811–817.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453–461.
   PubMed Web of Science ®Google Scholar
• Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009;106:3925–3929.
   PubMed Web of Science ®Google Scholar
• Coluccia AM, Vacca A, Dunach M, et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007;26:1456–1466.
   PubMed Web of Science ®Google Scholar
• Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006;25:7482–7491.
   PubMed Web of Science ®Google Scholar
• Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111:2843–2853.
   PubMed Web of Science ®Google Scholar
• Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood 2009;114:4186–4196.
   Google Scholar
• Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152–160.
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355–368.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 2006;95:775–781.
   Google Scholar
• Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408–2421.
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29–39.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038–3050.
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857–868.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Araki KY, Naka K, et al. foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007;1:101–112.
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010;463:676–680.
   PubMed Web of Science ®Google Scholar
• Peng C, Chen Y, Yang Z, et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010;115:626–635.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038–3050.
   PubMed Web of Science ®Google Scholar
• Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205–213.
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010;107:12469–12474.
   PubMed Web of Science ®Google Scholar
• Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010;18:74–87.
   PubMed Web of Science ®Google Scholar
• Abdel-Azim H, Zhu Y, Hollis R, et al. Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood 2008;111:4064–4074.
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783–792.
   PubMed Web of Science ®Google Scholar
• DuBois RN. Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst 2003;95:1028–1029.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Seed T, Jajeh A, et al. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res 1996;16:2589–2599.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Seed T, Plate JM, Jajeh A, Meng J, Harris JE. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk Res 1995;19:789–801.
   PubMed Web of Science ®Google Scholar
• Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794–2799.
   PubMed Web of Science ®Google Scholar
• Graham SM, Vass JK, Holyoake TL, Graham GJ. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007;25:3111–3120.
   PubMed Web of Science ®Google Scholar
• Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms of PML-nuclear body formation. Mol Cell 2006;24:331–339.
   PubMed Web of Science ®Google Scholar
• Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072–1078.
   PubMedGoogle Scholar
• Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010;9:3470–3478.
   PubMed Web of Science ®Google Scholar
• Bellodi C. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109–1123.
   PubMed Web of Science ®Google Scholar
• Salomoni P, Calabretta B. Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy 2009;5:1050–1051.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065–1069.
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010;95:1415–1419.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Schwarz M, Kim TD. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin Cancer Res 2010;16:1771–1780.
   PubMed Web of Science ®Google Scholar
• Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429–1435.
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Altavilla G. How cells respond to interferons. J Clin Oncol 2010;28:e439; author reply e440.
   PubMed Web of Science ®Google Scholar
• Stark GR. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev 2007;18:419–423.
   PubMed Web of Science ®Google Scholar
• Essers MAG, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904–908.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the ‘best’ therapy? Curr Oncol Rep 2010;12:302–313.
   PubMedGoogle Scholar
• Fava C, Saglio G. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? Semin Hematol 2010;47:319–326.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009;280:192–200.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751–1759.
   PubMed Web of Science ®Google Scholar
• Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17:427–442.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005;105:3303–3311.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Mayerhofer M, Krauth MT, et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005;65:9436–9444.
   PubMed Web of Science ®Google Scholar
• Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008;140:181–190.
   PubMedGoogle Scholar
• Kuroda J, Kimura S, Strasser A, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007;14:1667–1677.
   PubMed Web of Science ®Google Scholar
• Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006;103:14907–14912.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat 2007;10:207–217.
   PubMed Web of Science ®Google Scholar
• Campbell CJ, Lee JB, Levadoux-Martin M, et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010;116:1433–1442.
   PubMed Web of Science ®Google Scholar
• Lu M, Wang J, Li Y, et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F positive polycythemia vera hematopoietic progenitor cells. Blood 2010;116:4284–4287.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375–388.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295–8301.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299–305.
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430–5438.
   PubMed Web of Science ®Google Scholar
• Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005;121:1085–1095.
   PubMed Web of Science ®Google Scholar
• Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103–107.
   PubMed Web of Science ®Google Scholar
• Bartholomeusz GA, Talpaz M, Kapuria V, et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007;109:3470–3478.
   PubMed Web of Science ®Google Scholar
• Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010;70:9265–9276.
   PubMedGoogle Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–3428.
   PubMed Web of Science ®Google Scholar
• Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006;6:1163–1171.
   PubMed Web of Science ®Google Scholar
• Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010;14:412–420.
   PubMed Web of Science ®Google Scholar
• Peng C, Li D, Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 2007;6:2227–2231.
   PubMed Web of Science ®Google Scholar
• Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007;110:678–685.
   PubMed Web of Science ®Google Scholar
• Heaney NB, Pellicano F, Zhang B, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010;115:2241–2250.
   PubMed Web of Science ®Google Scholar
• Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 2010;116:81–84.
   PubMed Web of Science ®Google Scholar
• Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol 2006;406:554–565.
   PubMed Web of Science ®Google Scholar
• Gu Y, Filippi MD, Cancelas JA, et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003;302:445–449.
   PubMed Web of Science ®Google Scholar
• Lenaerts T, Pacheco JM, Traulsen A, Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 2010;95:900–907.
   PubMed Web of Science ®Google Scholar
• Sehl ME, Sinsheimer JS, Zhou H, Lange KL. Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res 2009;69:9481–9489.
   PubMed Web of Science ®Google Scholar
• Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010;6:829–836.
   PubMed Web of Science ®Google Scholar
• Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614–620.
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Sasaguri T. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci 2009;109:179–183.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883–897.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008;27:159–168.
   PubMedGoogle Scholar
• Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009;23:1432–1440.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047–2053.
   PubMed Web of Science ®Google Scholar
• Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 2009;16:2839–2854.
   PubMed Web of Science ®Google Scholar
• Cheng GZ, Park S, Shu S, et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 2008;8:2–6.
   PubMed Web of Science ®Google Scholar
• Yoon P, Giafis N, Smith J, et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 2006;5:2815–2823.
   PubMedGoogle Scholar
• Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med 2009;361:1202–1205.
   PubMed Web of Science ®Google Scholar
• Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010;466:765–768.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010;16:903–908.
   PubMed Web of Science ®Google Scholar
• Sengupta A, Banerjee D, Chandra S, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 2007;21:949–955.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li D, Li S. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell Cycle 2009;8:3488–3492.
   PubMed Web of Science ®Google Scholar
• Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663–676.
   PubMed Web of Science ®Google Scholar
• Emadi A, Gore SD. Arsenic trioxide - an old drug rediscovered. Blood Rev 2010;24:191–199.
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109–1123.
   PubMed Web of Science ®Google Scholar
• Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116:1329–1335.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 2003;9:4267–4273.
   PubMed Web of Science ®Google Scholar
• Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27(Suppl. 1):S149–S157.
   PubMed Web of Science ®Google Scholar
• Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010;10:232–256.
   PubMed Web of Science ®Google Scholar
• Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002;7:277–288.
   PubMedGoogle Scholar
• Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24:699–705.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Omacetaxine mepesuccinate–a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs 2008;11:356–372.
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446–1454.
   PubMed Web of Science ®Google Scholar
• Mak DH, Schober WD, Chen W, et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009;8:2509–2516.
   PubMed Web of Science ®Google Scholar
• Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009;15:1686–1697.
   PubMed Web of Science ®Google Scholar
• Kitzen JJ, de Jonge MJ, Lamers CH, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009;45:1764–1772.
   PubMed Web of Science ®Google Scholar